Y-mAbs Therapeutics Inc (NASDAQ:YMAB)
| 3.12 Delayed Data As of Mar 28 |  +0.08 / +2.64%Today’s Change | 2.70 Today|||52-Week Range 20.48 | -36.07% Year-to-Date |
Latest YMAB News | Press Releases
| Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue Estimates Mar 22 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 3.03 |
| Today’s open | 3.03 |
| Day’s range | 3.00 - 3.17 |
| Volume | 332,489 |
| Average volume (3 months) | 389,363 |
| Market cap | $132.8M |
Data as of 3:59pm ET, 03/28/2023
Growth & Valuation
| Earnings growth (last year) | +56.97% |
| Earnings growth (this year) | -104.59% |
| Earnings growth (next 5 years) | -88.68% |
| Revenue growth (last year) | +68.18% |
| P/E ratio | NM |
| Price/Sales | 20.06 |
| Price/Book | 0.74 |
Competitors
| ---- | ||
| SPPISpectrum Pharmaceuti... | -0.01 | -1.43% |
| GTHXG1 Therapeutics Inc | -0.15 | -5.38% |
| PRPHProphase Labs Inc | +0.13 | +1.59% |
Data as of 3:59pm ET, 03/28/2023
Financials
| Next reporting date | March 31, 2023 |
| EPS forecast (this quarter) | -$0.44 |
| Annual revenue (last year) | $34.9M |
| Annual profit (last year) | -$55.3M |
| Net profit margin | -158.39% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters New York, New York |
Forecasts
